Image

    Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-Analysis

    February 2022 in “ JAMA Dermatology ”
    Kanthi Bommareddy, Hassan Hamade, María A. López-Olivo … John S. Barbieri
    Studysummary This meta-analysis found that spironolactone use was linked to a decreased risk of prostate cancer but not to a significant risk increase for several other cancers, although the evidence certainty was low.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jamanetwork.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline The Journal of Clinical Endocrinology & Metabolism · 2009